Disclosure Of Interests In Other Entities [Text Block]
| Concept |
2024-01-01 to 2024-12-31 |
2024-01-01 to 2024-12-31 |
2024-01-01 to 2024-12-31 |
As at 2024-12-31 |
2024-01-01 to 2024-12-31 |
2024-01-01 to 2024-12-31 |
2024-01-01 to 2024-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disclosure of interests in other entities [text block] | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of interests in subsidiaries [text block] | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [text block] | — |
|
— | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [abstract] | |||||||||||||||
| Disclosure of subsidiaries [line items] | |||||||||||||||
| Current assets | — | — | — |
8,095,000,000
EUR
|
— | — | — | — | — |
7,565,000,000
EUR
|
— | — | — | — | — |
| Non-current assets | — | — | — |
6,245,000,000
EUR
|
— | — | — | — | — |
6,544,000,000
EUR
|
— | — | — | — | — |
| Current liabilities | — | — | — |
1,601,000,000
EUR
|
— | — | — | — | — |
3,853,000,000
EUR
|
— | — | — | — | — |
| Non-current liabilities | — | — | — |
7,432,000,000
EUR
|
— | — | — | — | — |
5,267,000,000
EUR
|
— | — | — | — | — |
| Revenue | — |
7,262,000,000
EUR
|
— | — | — | — | — | — |
6,846,000,000
EUR
|
— | — | — | — | — | — |
| Profit (loss) |
–
EUR
|
264,000,000
EUR
|
–
EUR
|
— |
–
EUR
|
–
EUR
|
264,000,000
EUR
|
–
EUR
|
1,270,000,000
EUR
|
— |
–
EUR
|
–
EUR
|
1,270,000,000
EUR
|
–
EUR
|
— |
| Comprehensive income |
–
EUR
|
336,000,000
EUR
|
–
EUR
|
— |
42,000,000
EUR
|
30,000,000
EUR
|
264,000,000
EUR
|
–
EUR
|
1,278,000,000
EUR
|
— |
20,000,000
EUR
|
–
EUR
|
1,267,000,000
EUR
|
31,000,000
EUR
|
— |
| Disclosure of interests in associates [text block] | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of associates [text block] | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of associates [abstract] | |||||||||||||||
| Disclosure of associates [line items] | |||||||||||||||
| Other comprehensive income |
–
EUR
|
72,000,000
EUR
|
–
EUR
|
— |
42,000,000
EUR
|
30,000,000
EUR
|
–
EUR
|
–
EUR
|
8,000,000
EUR
|
— |
20,000,000
EUR
|
–
EUR
|
–
EUR
|
28,000,000
EUR
|
— |
| Disclosure of interests in joint arrangements [text block] | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [text block] | — |
Die BioDarou P.J.S. Co. mit Sitz in Teheran, Iran, wird als Gemeinschaftsunternehmen at equity in den Konzernabschluss einbezogen.
|
— | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [abstract] | |||||||||||||||
| Disclosure of joint ventures [line items] | |||||||||||||||
| Cash and cash equivalents | — | — | — |
1,078,000,000
EUR
|
— | — | — | — | — |
1,081,000,000
EUR
|
— | — | — | — |
1,166,000,000
EUR
|
| Tax expense (income) | — |
202,000,000
EUR
|
— | — | — | — | — | — |
207,000,000
EUR
|
— | — | — | — | — | — |